@article{https://doi.org/10.17863/cam.37618,
doi = {10.17863/CAM.37618},
url = {https://www.repository.cam.ac.uk/handle/1810/290388},
author = {Earl,
Helena M and Hiller,
Louise and Vallier,
Anne-Laure and Loi,
Shrushma and McAdam,
Karen and Hughes-Davies,
Luke and Harnett,
Adrian N and Ah-See,
Mei-Lin and Simcock,
Richard and Rea,
Daniel and Raj,
Sanjay and Woodings,
Pamela and Harries,
Mark and Howe,
Donna and Raynes,
Kerry and Higgins,
Helen B and Wilcox,
Maggie and Plummer,
Chris and Mansi,
Janine and Gounaris,
Ioannis and Mahler-Araujo,
Betania and Provenzano,
Elena and Chhabra,
Anita and Abraham,
Jean E and Caldas,
Carlos and Hall,
Peter S and McCabe,
Christopher and Hulme,
Claire and Miles,
David and Wardley,
Andrew M and Cameron,
David A and Dunn,
Janet A and {PERSEPHONE Steering Committee And Trial Investigators}},
keywords = {Adult,
Aged,
Aged,
80 and over,
Antineoplastic Agents,
Immunological,
Breast Neoplasms,
Chemotherapy,
Adjuvant,
Disease-Free Survival,
Drug Administration Schedule,
Female,
Humans,
Infusions,
Intravenous,
Injections,
Subcutaneous,
Middle Aged,
Prospective Studies,
Receptor,
ErbB-2,
Trastuzumab,
Treatment Outcome,
United Kingdom,
Young Adult},
language = {en},
title = {6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.},
publisher = {Elsevier BV},
year = {2019},
copyright = {Creative Commons Attribution Non Commercial No Derivatives 4.0 International} }